Eli Lilly and Company's Biotechnology Discovery Research (BioTDR) organization is responsible for discovering and optimizing novel biotherapeutic medicines (proteins, peptides, antibodies, fusions, viral and non-viral genetic medicines, and bioconjugates) for advancement into clinical research in key areas of unmet medical need including diabetes, obesity and related complications, oncology, immunology, neuroscience, and more. Our current groups include: Africa, Middle East, Central Asia (AMECA), Black Employees at Lilly (BE@Lilly), Chinese Culture Network (CCN), EnAble, Evolve, Lilly Indian Network (LIN), Organization of Latinx at Lilly (OLA), Pride (LGBTQ+ Allies), Veterans Leadership Network (VLN) and Women’s Initiative for Leading at Lilly (WILL).